{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T19:30:09Z","timestamp":1771875009477,"version":"3.50.1"},"reference-count":212,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.beha.2011.03.002","type":"journal-article","created":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T12:35:13Z","timestamp":1304944513000},"page":"231-256","source":"Crossref","is-referenced-by-count":17,"title":["Novel antibodies against follicular non-Hodgkin\u2019s lymphoma"],"prefix":"10.1016","volume":"24","author":[{"given":"Tom","family":"van Meerten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Hagenbeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.beha.2011.03.002_bib1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"9","author":"Anderson","year":"1998","journal-title":"Ann Oncol"},{"issue":"Suppl. 4","key":"10.1016\/j.beha.2011.03.002_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/annonc\/mdp148","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"Dreyling","year":"2009","journal-title":"Ann Oncol"},{"issue":"5 Suppl. 5","key":"10.1016\/j.beha.2011.03.002_bib3","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.beha.2011.03.002_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0609.2006.00789.x","article-title":"The therapeutic use of rituximab in non-Hodgkin\u2019s lymphoma","volume":"67","author":"Marcus","year":"2007","journal-title":"Eur J Haematol Suppl"},{"issue":"5517","key":"10.1016\/j.beha.2011.03.002_bib5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.beha.2011.03.002_bib6","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2011.03.002_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003805.pub2","article-title":"Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin\u2019s lymphoma","author":"Schulz","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.beha.2011.03.002_bib8","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1200\/JCO.2008.19.8457","article-title":"Maintenance or eradication of residual disease in indolent lymphoma: where do we stand?","volume":"27","author":"Hagenbeek","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2011.03.002_bib9","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma\u2013a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.002_bib10","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"10.1016\/j.beha.2011.03.002_bib11","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/jco.2010.28.15_suppl.8004","article-title":"Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy","volume":"28","author":"Salles","year":"2010","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"17","key":"10.1016\/j.beha.2011.03.002_bib12","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2011.03.002_bib13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"issue":"2","key":"10.1016\/j.beha.2011.03.002_bib14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J Immunol"},{"issue":"13","key":"10.1016\/j.beha.2011.03.002_bib15","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-06-0066","article-title":"Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity","volume":"12","author":"van Meerten","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.beha.2011.03.002_bib16","doi-asserted-by":"crossref","first-page":"10556","DOI":"10.1158\/0008-5472.CAN-07-1811","article-title":"In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab","volume":"67","author":"Macor","year":"2007","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.beha.2011.03.002_bib17","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2007-02-074716","article-title":"NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement","volume":"111","author":"Wang","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2011.03.002_bib18","first-page":"611","article-title":"Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression","volume":"5","author":"Davis","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.beha.2011.03.002_bib19","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.4049\/jimmunol.176.4.2600","article-title":"The shaving reaction: rituximab\/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes","volume":"176","author":"Beum","year":"2006","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.beha.2011.03.002_bib20","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2011.03.002_bib21","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","article-title":"Fc gammaRIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L\/R\/H phenotype","volume":"90","author":"Koene","year":"1997","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2011.03.002_bib22","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1172\/JCI119616","article-title":"A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease","volume":"100","author":"Wu","year":"1997","journal-title":"J Clin Invest"},{"issue":"1\u20132","key":"10.1016\/j.beha.2011.03.002_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jim.2005.06.018","article-title":"CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells","volume":"304","author":"Bowles","year":"2005","journal-title":"J Immunol Methods"},{"issue":"3","key":"10.1016\/j.beha.2011.03.002_bib24","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1371\/journal.pone.0000326","article-title":"Serial killing of tumor cells by human natural killer cells\u2013enhancement by therapeutic antibodies","volume":"2","author":"Bhat","year":"2007","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.beha.2011.03.002_bib25","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-06-1860","article-title":"Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab","volume":"13","author":"Berdeja","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.beha.2011.03.002_bib26","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.4049\/jimmunol.172.5.3280","article-title":"Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia","volume":"172","author":"Kennedy","year":"2004","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.beha.2011.03.002_bib27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(07)70106-7","article-title":"Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia","volume":"8","author":"Klepfish","year":"2007","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.beha.2011.03.002_bib28","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/qjmed\/hcn085","article-title":"Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL","volume":"101","author":"Klepfish","year":"2008","journal-title":"QJM"},{"issue":"16","key":"10.1016\/j.beha.2011.03.002_bib29","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2011.03.002_bib30","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/1078-0432.CCR-08-1511","article-title":"Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG","volume":"15","author":"Ghosh","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.beha.2011.03.002_bib31","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/01.cji.0000155050.03916.04","article-title":"Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis","volume":"28","author":"Vugmeyster","year":"2005","journal-title":"J Immunother"},{"issue":"2","key":"10.1016\/j.beha.2011.03.002_bib32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.seminhematol.2010.01.007","article-title":"CD20-targeted therapy: the next generation of antibodies","volume":"47","author":"van Meerten","year":"2010","journal-title":"Semin Hematol"},{"issue":"20","key":"10.1016\/j.beha.2011.03.002_bib33","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1016\/S0021-9258(19)81618-6","article-title":"Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes","volume":"263","author":"Tedder","year":"1988","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.beha.2011.03.002_bib34","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.4049\/jimmunol.142.7.2560","article-title":"Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1)","volume":"142","author":"Tedder","year":"1989","journal-title":"J Immunol"},{"issue":"43","key":"10.1016\/j.beha.2011.03.002_bib35","doi-asserted-by":"crossref","first-page":"42427","DOI":"10.1074\/jbc.M308802200","article-title":"Store-operated cation entry mediated by CD20 in membrane rafts","volume":"278","author":"Li","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beha.2011.03.002_bib36","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M800784200","article-title":"CD20 homo-oligomers physically associate with the B cell antigen receptor; dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin binding proteins","author":"Polyak","year":"2008","journal-title":"J Biol Chem"},{"issue":"25","key":"10.1016\/j.beha.2011.03.002_bib37","doi-asserted-by":"crossref","first-page":"16971","DOI":"10.1074\/jbc.M708459200","article-title":"Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling","volume":"283","author":"Walshe","year":"2008","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.beha.2011.03.002_bib38","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1172\/JCI40231","article-title":"CD20 deficiency in humans results in impaired T cell-independent antibody responses","volume":"120","author":"Kuijpers","year":"2010","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.beha.2011.03.002_bib39","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"},{"issue":"11\u201312","key":"10.1016\/j.beha.2011.03.002_bib40","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.molimm.2009.04.009","article-title":"Structure of the Fab fragment of therapeutic antibody ofatumumab provides insights into the recognition mechanism with CD20","volume":"46","author":"Du","year":"2009","journal-title":"Mol Immunol"},{"issue":"6","key":"10.1016\/j.beha.2011.03.002_bib41","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2011.03.002_bib42","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2002-06-1761","article-title":"Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts","volume":"101","author":"Cragg","year":"2003","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2011.03.002_bib43","first-page":"5480","article-title":"CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts","volume":"63","author":"Chan","year":"2003","journal-title":"Cancer Res"},{"issue":"24","key":"10.1016\/j.beha.2011.03.002_bib44","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1182\/blood-2009-06-225474","article-title":"Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma","volume":"114","author":"Li","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2011.03.002_bib45","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1158\/0008-5472.CAN-07-6663","article-title":"Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity","volume":"68","author":"Li","year":"2008","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.beha.2011.03.002_bib46","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1182\/blood-2008-11-188896","article-title":"A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody\/radioantibody therapy","volume":"113","author":"Sharkey","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2011.03.002_bib47","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1182\/blood-2008-04-149161","article-title":"Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation","volume":"112","author":"Beers","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.002_bib48","article-title":"Ofatumumab, a human Mab targeting a membrane-proximal small-loop epitope on CD20, induces potent NK cell-mediated ADCC","author":"Craigen","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"Suppl. 15","key":"10.1016\/j.beha.2011.03.002_bib49","doi-asserted-by":"crossref","first-page":"8095","DOI":"10.1200\/jco.2010.28.15_suppl.8095","article-title":"Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma","volume":"28","author":"Barth","year":"2010","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"12","key":"10.1016\/j.beha.2011.03.002_bib50","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","article-title":"First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial","volume":"111","author":"Hagenbeek","year":"2008","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2011.03.002_bib51","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.002_bib52","article-title":"Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma","author":"Hagenbeek","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"Suppl. 15","key":"10.1016\/j.beha.2011.03.002_bib53","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1200\/jco.2010.28.15_suppl.8042","article-title":"Ofatumumab combined with CHOP in previously untreated patients with follicular lymphoma (FL)","volume":"28","author":"Czuczman","year":"2010","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.beha.2011.03.002_bib54","doi-asserted-by":"crossref","unstructured":"Wierda G, Kipps T, Mayer J, et\u00a0al. High activity of single-agent ofatumumab, a novel CD20 monoclonal antibody in fludarabine- and alemtuzumab-refractory or bulky fludarabine - refractory chronic lymphocytic leukemia, regardless of prior rituximab exposure. EHA annual meeting 0919, 6\u20136-2009.","DOI":"10.3816\/CLM.2009.n.098"},{"key":"10.1016\/j.beha.2011.03.002_bib55","doi-asserted-by":"crossref","unstructured":"Wierda W, Kipps T, Griskevicius L, et\u00a0al. Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, phase II trial. ASH Annual Meeting Abstracts, 8-12-2009.","DOI":"10.1182\/blood.V114.22.207.207"},{"issue":"5","key":"10.1016\/j.beha.2011.03.002_bib56","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2008-07-168146","article-title":"Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody","volume":"113","author":"Goldenberg","year":"2009","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2011.03.002_bib57","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1200\/JCO.2008.19.9117","article-title":"Humanized anti-CD20 antibody, veltuzumab, in refractory\/recurrent non-Hodgkin\u2019s lymphoma: phase I\/II results","volume":"27","author":"Morschhauser","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.002_bib58","article-title":"Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab for treatment of indolent B-cell malignancies","author":"Negrea","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"20","key":"10.1016\/j.beha.2011.03.002_bib59","doi-asserted-by":"crossref","first-page":"8384","DOI":"10.1158\/0008-5472.CAN-08-2033","article-title":"Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics","volume":"68","author":"Rossi","year":"2008","journal-title":"Cancer Res"},{"issue":"16 Pt 1","key":"10.1016\/j.beha.2011.03.002_bib60","first-page":"5866","article-title":"Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin\u2019s lymphoma severe combined immunodeficiency mouse model","volume":"9","author":"Hernandez-Ilizaliturri","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.beha.2011.03.002_bib61","first-page":"645","article-title":"Interim results of a phase I\/II study of ocrelizumab, a New humanised Anti-CD20 antibody in patients with Relapsed\/Refractory follicular non-Hodgkin\u2019s lymphoma","volume":"110","author":"Morschhauser","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"9","key":"10.1016\/j.beha.2011.03.002_bib62","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/annonc\/mdq027","article-title":"Results of a phase I\/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed\/refractory follicular lymphoma","volume":"21","author":"Morschhauser","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2011.03.002_bib63","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/asheducation-2007.1.226","article-title":"Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects","volume":"2007","author":"Maloney","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.beha.2011.03.002_bib64","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/asheducation-2007.1.233","article-title":"Monoclonal antibodies for B-cell lymphomas: rituximab and beyond","author":"Bello","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.beha.2011.03.002_bib65","article-title":"A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed\/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics","author":"Friedberg","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"8","key":"10.1016\/j.beha.2011.03.002_bib66","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1182\/blood-2006-04-020057","article-title":"Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab","volume":"108","author":"Bowles","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2011.03.002_bib67","first-page":"348","article-title":"Anti-CD20 monoclonal antibody (mAb) with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab (R)","volume":"106","author":"Weiner","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"22","key":"10.1016\/j.beha.2011.03.002_bib68","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2011.03.002_bib69","first-page":"234","article-title":"A phase I\/II study of RO5072759 (GA101) in patients with relapsed\/refractory CD20 + malignant disease","volume":"112","author":"Salles","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"22","key":"10.1016\/j.beha.2011.03.002_bib70","first-page":"1704","article-title":"Phase I study of RO5072759 (GA101) in patients with relapsed\/refractory CD20 + non-hodgkin lymphoma (NHL)","volume":"114","author":"Salles","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"22","key":"10.1016\/j.beha.2011.03.002_bib71","first-page":"934","article-title":"A phase I study of GA101 (RO5072759) monotherapy followed by maintenance in patients with multiply relapsed\/refractory CD20 + malignant disease","volume":"114","author":"Sehn","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.beha.2011.03.002_bib72","doi-asserted-by":"crossref","unstructured":"Salles A, Morschhauser F, Thieblemont C, et\u00a0al. Promising efficacy with the new anti-CD20 antibody GA101 in heavily pre-treated patients - first results from a phase II study in patients with relapsed\/refractory indolent NHL (iNHL). EHA annual meeting. 1-6-2010.","DOI":"10.1182\/blood.V116.21.2868.2868"},{"issue":"8","key":"10.1016\/j.beha.2011.03.002_bib73","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1158\/1078-0432.CCR-08-1694","article-title":"CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells","volume":"15","author":"Hayden-Ledbetter","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.beha.2011.03.002_bib74","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.clinthera.2008.10.017","article-title":"Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study","volume":"30","author":"Burge","year":"2008","journal-title":"Clin Ther"},{"issue":"10","key":"10.1016\/j.beha.2011.03.002_bib75","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1016\/S0021-9258(18)53139-2","article-title":"CD22, a B cell-specific immunoglobulin superfamily member, is a sialic acid-binding lectin","volume":"268","author":"Sgroi","year":"1993","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.beha.2011.03.002_bib76","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0960-9822(06)00057-1","article-title":"CD22 is a negative regulator of B-cell receptor signalling","volume":"7","author":"Nitschke","year":"1997","journal-title":"Curr Biol"},{"issue":"9","key":"10.1016\/j.beha.2011.03.002_bib77","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.4049\/jimmunol.0901719","article-title":"CD22 expression mediates the regulatory functions of peritoneal B-1a cells during the remission phase of contact hypersensitivity reactions","volume":"184","author":"Nakashima","year":"2010","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.beha.2011.03.002_bib78","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1006\/smim.1998.0121","article-title":"CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor","volume":"10","author":"Sato","year":"1998","journal-title":"Semin Immunol"},{"issue":"17\u201318","key":"10.1016\/j.beha.2011.03.002_bib79","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/0161-5890(95)00080-1","article-title":"Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia\/lymphoma antibody, LL2","volume":"32","author":"Leung","year":"1995","journal-title":"Mol Immunol"},{"issue":"10 Pt 2","key":"10.1016\/j.beha.2011.03.002_bib80","first-page":"3982S","article-title":"Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties","volume":"9","author":"Carnahan","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.beha.2011.03.002_bib81","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.molimm.2006.05.007","article-title":"Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab","volume":"44","author":"Carnahan","year":"2007","journal-title":"Mol Immunol"},{"issue":"16","key":"10.1016\/j.beha.2011.03.002_bib82","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","article-title":"Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin\u2019s lymphoma","volume":"21","author":"Leonard","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.002_bib83","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/cncr.23890","article-title":"Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma","volume":"113","author":"Leonard","year":"2008","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.beha.2011.03.002_bib84","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","article-title":"Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin\u2019s lymphoma","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2011.03.002_bib85","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1002\/cncr.22342","article-title":"A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma","volume":"107","author":"Micallef","year":"2006","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.beha.2011.03.002_bib86","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1158\/1078-0432.CCR-03-0493","article-title":"Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin\u2019s lymphoma","volume":"10","author":"Stein","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.beha.2011.03.002_bib87","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood-2007-08-110072","article-title":"Bispecific anti-CD20\/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action","volume":"111","author":"Qu","year":"2008","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.beha.2011.03.002_bib88","doi-asserted-by":"crossref","first-page":"6161","DOI":"10.1182\/blood-2008-10-187138","article-title":"Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20\/CD22 antibodies in lymphoma","volume":"113","author":"Rossi","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2011.03.002_bib89","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00262-004-0572-2","article-title":"Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22","volume":"54","author":"DiJoseph","year":"2005","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"10.1016\/j.beha.2011.03.002_bib90","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","article-title":"Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies","volume":"103","author":"DiJoseph","year":"2004","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.beha.2011.03.002_bib91","doi-asserted-by":"crossref","first-page":"8620","DOI":"10.1158\/1078-0432.CCR-04-1134","article-title":"Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma","volume":"10","author":"DiJoseph","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.beha.2011.03.002_bib92","first-page":"2490","article-title":"Antibody-targeted chemotherapy with immunoconjugates of calicheamicin: differential anti-tumor activity of conjugated calicheamicin targeted to B-cell lymphoma via B-cell lineage specific molecules CD19, CD20 and CD22","volume":"104","author":"DiJoseph","year":"2004","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"1","key":"10.1016\/j.beha.2011.03.002_bib93","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1158\/1078-0432.CCR-05-1905","article-title":"Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin\u2019s B-cell lymphoma","volume":"12","author":"DiJoseph","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.beha.2011.03.002_bib94","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin\u2019s lymphoma: results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2011.03.002_bib95","first-page":"584","article-title":"Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity including survival in patients with recurrent\/refractory follicular or \u2018aggressive\u2019 lymphoma","volume":"114","author":"Dang","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"2","key":"10.1016\/j.beha.2011.03.002_bib96","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0268-960X(96)90040-5","article-title":"B7-mediated costimulation and the immune response","volume":"10","author":"Schultze","year":"1996","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.beha.2011.03.002_bib97","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3816\/CLM.2003.n.008","article-title":"Initial trials of anti-CD80 monoclonal antibody (galiximab) therapy for patients with relapsed or refractory follicular lymphoma","volume":"3","author":"Younes","year":"2003","journal-title":"Clin Lymphoma"},{"issue":"22","key":"10.1016\/j.beha.2011.03.002_bib98","first-page":"1953","article-title":"CD80 (B7.1) Is expressed on both malignant B cells and tumor infiltrating T cells in non-Hodgkin\u2019s lymphomas","volume":"114","author":"Tangri","year":"2009","journal-title":"Blood ASH Annual Meeting Abstracts"},{"issue":"3","key":"10.1016\/j.beha.2011.03.002_bib99","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1517\/14712591003596318","article-title":"Galiximab: a review","volume":"10","author":"Bhat","year":"2010","journal-title":"Expert Opin Biol Ther"},{"issue":"19","key":"10.1016\/j.beha.2011.03.002_bib100","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1200\/JCO.2005.09.018","article-title":"Phase I\/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma","volume":"23","author":"Czuczman","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2011.03.002_bib101","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/annonc\/mdm114","article-title":"A phase I\/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma","volume":"18","author":"Leonard","year":"2007","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.beha.2011.03.002_bib102","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.67.1.2","article-title":"CD40\u2013CD40 ligand","volume":"67","author":"van Kooten","year":"2000","journal-title":"J Leukoc Biol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.002_bib103","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1002\/cncr.21816","article-title":"Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies","volume":"106","author":"Hock","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.beha.2011.03.002_bib104","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/00001622-199909000-00007","article-title":"The dynamics of life and death of malignant lymphocytes","volume":"11","author":"Younes","year":"1999","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2011.03.002_bib105","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/172460089901400303","article-title":"CD30\/CD30 ligand and CD40\/CD40 ligand in malignant lymphoid disorders","volume":"14","author":"Younes","year":"1999","journal-title":"Int J Biol Markers"},{"issue":"18","key":"10.1016\/j.beha.2011.03.002_bib106","doi-asserted-by":"crossref","first-page":"8331","DOI":"10.1158\/0008-5472.CAN-05-0095","article-title":"Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40","volume":"65","author":"Law","year":"2005","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.beha.2011.03.002_bib107","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/sj.bjc.6604812","article-title":"Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40","volume":"100","author":"Oflazoglu","year":"2009","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.beha.2011.03.002_bib108","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/sj.bjp.0706828","article-title":"Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates","volume":"148","author":"Kelley","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"26","key":"10.1016\/j.beha.2011.03.002_bib109","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2008.21.3017","article-title":"Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin\u2019s lymphoma","volume":"27","author":"Advani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2011.03.002_bib110","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3109\/10428190903440946","article-title":"A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia","volume":"51","author":"Furman","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.beha.2011.03.002_bib111","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3324\/haematol.2009.008003","article-title":"A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma","volume":"95","author":"Hussein","year":"2010","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.beha.2011.03.002_bib112","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood.V106.11.1472.1472","article-title":"CHIR-12.12, an antagonist anti-CD40 antibody, exhibits greater ADCC than rituximab against a variety of malignant B cells: evaluation of Fc{gamma}RIIIa polymorphism and ADCC response","volume":"106","author":"Luqman","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2011.03.002_bib113","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/blood-2007-04-084756","article-title":"The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells","volume":"112","author":"Luqman","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2011.03.002_bib114","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1074-7613(00)80418-5","article-title":"The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity","volume":"6","author":"Tedder","year":"1997","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.beha.2011.03.002_bib115","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.4049\/jimmunol.158.10.4662","article-title":"CD19 expression levels regulate B lymphocyte development: human CD19 restores normal function in mice lacking endogenous CD19","volume":"158","author":"Sato","year":"1997","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.beha.2011.03.002_bib116","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.4049\/jimmunol.158.7.3062","article-title":"Membrane IgM-induced tyrosine phosphorylation of CD19 requires a CD19 domain that mediates association with components of the B cell antigen receptor complex","volume":"158","author":"Carter","year":"1997","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.beha.2011.03.002_bib117","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood.V83.5.1329.1329","article-title":"Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest","volume":"83","author":"Ghetie","year":"1994","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2011.03.002_bib118","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1182\/blood.V92.12.4750","article-title":"Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents \u201cveto\u201d apoptosis of antibody-targeted cytotoxic T cells","volume":"92","author":"Daniel","year":"1998","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.beha.2011.03.002_bib119","first-page":"3783","article-title":"Potentiation by interleukin 2 of Burkitt\u2019s lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model","volume":"49","author":"Vuist","year":"1989","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.beha.2011.03.002_bib120","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/BF01741331","article-title":"Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody","volume":"32","author":"Hekman","year":"1991","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.beha.2011.03.002_bib121","first-page":"37","article-title":"Treatment of low-grade non-Hodgkin\u2019s lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19","volume":"40","author":"Vlasveld","year":"1995","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.beha.2011.03.002_bib122","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.1993.11.4.726","article-title":"Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms","volume":"11","author":"Grossbard","year":"1993","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2011.03.002_bib123","first-page":"840","article-title":"Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model","volume":"55","author":"Hooijberg","year":"1995","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.beha.2011.03.002_bib124","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","article-title":"Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia","volume":"68","author":"Horton","year":"2008","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.beha.2011.03.002_bib125","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood-2009-06-229039","article-title":"CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody","volume":"115","author":"Awan","year":"2010","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.beha.2011.03.002_bib126","first-page":"4310","article-title":"Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies","volume":"53","author":"Bohlen","year":"1993","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.beha.2011.03.002_bib127","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ijc.20417","article-title":"Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells","volume":"112","author":"Reusch","year":"2004","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.beha.2011.03.002_bib128","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1068>3.0.CO;2-D","article-title":"Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation","volume":"91","author":"Manzke","year":"2001","journal-title":"Int J Cancer"},{"issue":"5\u20136","key":"10.1016\/j.beha.2011.03.002_bib129","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/10428199509112195","article-title":"Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy","volume":"19","author":"Haagen","year":"1995","journal-title":"Leuk Lymphoma"},{"issue":"5891","key":"10.1016\/j.beha.2011.03.002_bib130","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.beha.2011.03.002_bib131","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes","volume":"95","author":"Loffler","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2011.03.002_bib132","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.beha.2011.03.002_bib133","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1158\/1078-0432.CCR-08-2808","article-title":"Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin\u2019s lymphoma","volume":"15","author":"Al-Katib","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.beha.2011.03.002_bib134","first-page":"585","article-title":"Phase I multi-dose escalation study of the Anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous (IV) infusion every 3 Weeks to patients with relapsed\/ refractory B-Cell non-Hodgkin\u2019s lymphoma (NHL)","volume":"114","author":"Younes","year":"2009","journal-title":"Blood ASH Annual Meeting Abstracts"},{"issue":"18 Pt 2","key":"10.1016\/j.beha.2011.03.002_bib135","doi-asserted-by":"crossref","first-page":"5556s","DOI":"10.1158\/1078-0432.CCR-07-1167","article-title":"CD74: a new candidate target for the immunotherapy of B-cell neoplasms","volume":"13","author":"Stein","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.beha.2011.03.002_bib136","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1182\/blood-2005-11-4334","article-title":"Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival","volume":"107","author":"Starlets","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2011.03.002_bib137","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1084\/jem.20030286","article-title":"MIF signal transduction initiated by binding to CD74","volume":"197","author":"Leng","year":"2003","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.beha.2011.03.002_bib138","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2004-03-0890","article-title":"Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies","volume":"104","author":"Stein","year":"2004","journal-title":"Blood"},{"issue":"5118","key":"10.1016\/j.beha.2011.03.002_bib139","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.8327892","article-title":"Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates","volume":"261","author":"Trail","year":"1993","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.beha.2011.03.002_bib140","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1158\/1078-0432.CCR-05-0204","article-title":"Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys","volume":"11","author":"Sapra","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.beha.2011.03.002_bib141","first-page":"6567","article-title":"Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate","volume":"9","author":"Griffiths","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.beha.2011.03.002_bib142","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1182\/blood-2005-03-1033","article-title":"Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease\/anti-CD74 humanized IgG4 antibody immunotoxin","volume":"106","author":"Chang","year":"2005","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2011.03.002_bib143","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V75.12.2375.2375","article-title":"Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes","volume":"75","author":"Gingrich","year":"1990","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2011.03.002_bib144","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ijc.1366","article-title":"Humanization and characterization of the anti-HLA-DR antibody 1D10","volume":"93","author":"Kostelny","year":"2001","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.beha.2011.03.002_bib145","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1046\/j.1365-2141.2002.03722.x","article-title":"Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10\u2013a humanized human leucocyte antigen DR antibody","volume":"118","author":"Stockmeyer","year":"2002","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.beha.2011.03.002_bib146","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1080\/10428190290026376","article-title":"In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells","volume":"43","author":"Shi","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.beha.2011.03.002_bib147","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.3109\/10428190903370379","article-title":"Targeting HLA-DR","volume":"50","author":"Tay","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.beha.2011.03.002_bib148","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3816\/CLM.2001.n.026","article-title":"Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma","volume":"2","author":"Brown","year":"2001","journal-title":"Clin Lymphoma"},{"issue":"12","key":"10.1016\/j.beha.2011.03.002_bib149","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3109\/10428190903186486","article-title":"A phase I\/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia","volume":"50","author":"Lin","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"Suppl. 16","key":"10.1016\/j.beha.2011.03.002_bib150","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1200\/jco.2005.23.16_suppl.6607","article-title":"Phase 1 study of combination rituximab with apolizumab in relapsed\/refractory B-cell lymphoma and chronic lymphocytic leukemia","volume":"23","author":"Dunleavy","year":"2005","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.beha.2011.03.002_bib151","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2009-06-228288","article-title":"Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyper-activation of ERK and JNK MAP kinase signaling pathways","author":"Stein","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2011.03.002_bib152","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-04-017921","article-title":"Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab","volume":"108","author":"Stein","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2011.03.002_bib153","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/cbr.2004.19.545","article-title":"Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells","volume":"19","author":"Liu","year":"2004","journal-title":"Cancer Biother Radiopharm"},{"issue":"2","key":"10.1016\/j.beha.2011.03.002_bib154","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/hon.2900070207","article-title":"A phase 1a clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies","volume":"7","author":"Hu","year":"1989","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.beha.2011.03.002_bib155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/hyb.1999.18.1","article-title":"Milestones in the development of Lym-1 therapy","volume":"18","author":"DeNardo","year":"1999","journal-title":"Hybridoma"},{"issue":"12","key":"10.1016\/j.beha.2011.03.002_bib156","first-page":"2014","article-title":"A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin\u2019s lymphoma","volume":"40","author":"O\u2019Donnell","year":"1999","journal-title":"J Nucl Med"},{"issue":"5C","key":"10.1016\/j.beha.2011.03.002_bib157","first-page":"3647","article-title":"A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin\u2019s lymphoma","volume":"20","author":"O\u2019Donnell","year":"2000","journal-title":"Anticancer Res"},{"issue":"19 Pt 2","key":"10.1016\/j.beha.2011.03.002_bib158","doi-asserted-by":"crossref","first-page":"7075s","DOI":"10.1158\/1078-0432.CCR-1004-0008","article-title":"Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies","volume":"11","author":"DeNardo","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.beha.2011.03.002_bib159","first-page":"729","article-title":"Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin\u2019s lymphoma","volume":"31","author":"DeNardo","year":"2007","journal-title":"Int J Oncol"},{"issue":"6","key":"10.1016\/j.beha.2011.03.002_bib160","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1089\/cbr.2006.21.645","article-title":"Direct antilymphoma activity of novel, first-generation \u201cantibody mimics\u201d that bind HLA-DR10-positive non-Hodgkin\u2019s lymphoma cells","volume":"21","author":"West","year":"2006","journal-title":"Cancer Biother Radiopharm"},{"issue":"8","key":"10.1016\/j.beha.2011.03.002_bib161","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.2967\/jnumed.107.041095","article-title":"Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma","volume":"48","author":"DeNardo","year":"2007","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.beha.2011.03.002_bib162","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0955-0674(99)80034-9","article-title":"Apoptosis control by death and decoy receptors","volume":"11","author":"Ashkenazi","year":"1999","journal-title":"Curr Opin Cell Biol"},{"issue":"8","key":"10.1016\/j.beha.2011.03.002_bib163","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/sj.bjc.6602487","article-title":"HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo","volume":"92","author":"Pukac","year":"2005","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.beha.2011.03.002_bib164","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2141.2005.05656.x","article-title":"Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death","volume":"130","author":"Georgakis","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.beha.2011.03.002_bib165","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/1535-7163.MCT-08-0918","article-title":"Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib","volume":"8","author":"Luster","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.beha.2011.03.002_bib166","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1046\/j.1365-2141.1997.4393250.x","article-title":"Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies","volume":"99","author":"Snell","year":"1997","journal-title":"Br J Haematol"},{"issue":"15 Pt 1","key":"10.1016\/j.beha.2011.03.002_bib167","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-07-0680","article-title":"Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20","volume":"13","author":"Maddipatla","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.beha.2011.03.002_bib168","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1200\/JCO.2006.08.8898","article-title":"Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1","volume":"25","author":"Tolcher","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2011.03.002_bib169","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.lungcan.2007.12.011","article-title":"Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer","volume":"61","author":"Greco","year":"2008","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.beha.2011.03.002_bib170","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/sj.bjc.6605507","article-title":"Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer","volume":"102","author":"Trarbach","year":"2010","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.beha.2011.03.002_bib171","first-page":"489","article-title":"Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed\/refractory non-Hodgkin\u2019s lymphoma (NHL)","volume":"106","author":"Younes","year":"2005","journal-title":"Blood ASH Annual Meeting Abstracts"},{"issue":"2","key":"10.1016\/j.beha.2011.03.002_bib172","first-page":"421","article-title":"Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo","volume":"28","author":"Zeng","year":"2006","journal-title":"Int J Oncol"},{"issue":"2","key":"10.1016\/j.beha.2011.03.002_bib173","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/annonc\/mdp292","article-title":"Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors","volume":"21","author":"Wakelee","year":"2010","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.beha.2011.03.002_bib174","doi-asserted-by":"crossref","DOI":"10.4161\/cbt.9.8.11264","article-title":"Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types","volume":"9","author":"Kaplan-Lefko","year":"2010","journal-title":"Cancer Biol Ther"},{"issue":"Suppl. 18","key":"10.1016\/j.beha.2011.03.002_bib175","doi-asserted-by":"crossref","first-page":"8078","DOI":"10.1200\/jco.2007.25.18_suppl.8078","article-title":"A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L\/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma","volume":"25","author":"Yee","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"12","key":"10.1016\/j.beha.2011.03.002_bib176","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1182\/blood-2007-02-076075","article-title":"Cooperation of the proapoptotic receptor agonist rhApo2L\/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts","volume":"110","author":"Daniel","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2011.03.002_bib177","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/blood-2007-03-082024","article-title":"Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines","volume":"111","author":"Pathan","year":"2008","journal-title":"Blood"},{"issue":"15 Pt 1","key":"10.1016\/j.beha.2011.03.002_bib178","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1158\/1078-0432.CCR-06-1463","article-title":"Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"13","author":"Byrd","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.beha.2011.03.002_bib179","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2009-08-237727","article-title":"Phase 1\/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"115","author":"Byrd","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2011.03.002_bib180","doi-asserted-by":"crossref","first-page":"6088","DOI":"10.1074\/jbc.270.11.6088","article-title":"Primary structure of CD52","volume":"270","author":"Treumann","year":"1995","journal-title":"J Biol Chem"},{"issue":"2\u20133","key":"10.1016\/j.beha.2011.03.002_bib181","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejphar.2005.03.024","article-title":"Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity","volume":"514","author":"Nuckel","year":"2005","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10.1016\/j.beha.2011.03.002_bib182","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/0161-5890(93)90155-5","article-title":"Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen","volume":"30","author":"Xia","year":"1993","journal-title":"Mol Immunol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.002_bib183","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"issue":"35","key":"10.1016\/j.beha.2011.03.002_bib184","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2011.03.002_bib185","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2011.03.002_bib186","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2011.03.002_bib187","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2011.03.002_bib188","first-page":"3736","article-title":"The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin\u2019s disease","volume":"62","author":"Wahl","year":"2002","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.beha.2011.03.002_bib189","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1182\/blood-2007-06-097014","article-title":"Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30","volume":"110","author":"Oflazoglu","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2011.03.002_bib190","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/sj.leu.2403884","article-title":"Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin\u2019s disease cells to conventional chemotherapeutics","volume":"19","author":"Cerveny","year":"2005","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.beha.2011.03.002_bib191","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.1158\/1078-0432.CCR-09-0162","article-title":"A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders","volume":"15","author":"Duvic","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.beha.2011.03.002_bib192","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","article-title":"A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"146","author":"Forero-Torres","year":"2009","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2011.03.002_bib193","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood-2007-07-099317","article-title":"A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies","volume":"111","author":"Bartlett","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.002_bib194","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdq211","article-title":"Serious pulmonary toxicity in patients with Hodgkin\u2019s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an Fc{gamma}RIIIa-158 V\/F polymorphism","author":"Blum","year":"2010","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.002_bib195","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1182\/blood-2003-02-0515","article-title":"The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma","volume":"102","author":"Borchmann","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2011.03.002_bib196","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00002371-200409000-00003","article-title":"Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines","volume":"27","author":"Heuck","year":"2004","journal-title":"J Immunother"},{"issue":"19","key":"10.1016\/j.beha.2011.03.002_bib197","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","article-title":"Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma","volume":"25","author":"Ansell","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.002_bib198","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1158\/1078-0432.CCR-08-3222","article-title":"In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma","volume":"15","author":"Cardarelli","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.beha.2011.03.002_bib199","first-page":"2340","article-title":"XmAbTM2513, an Fc engineered humanized Anti-CD30 monoclonal antibody, has potent in vitro and in vivo activities, and has the potential for treating hematologic malignancies","volume":"110","author":"Lawrence","year":"2007","journal-title":"Blood ASH Annual Meeting Abstracts"},{"issue":"21","key":"10.1016\/j.beha.2011.03.002_bib200","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","article-title":"Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy","volume":"20","author":"Dvorak","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2011.03.002_bib201","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1034\/j.1600-0609.2002.01609.x","article-title":"Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin\u2019s lymphoma","volume":"68","author":"Niitsu","year":"2002","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.beha.2011.03.002_bib202","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V96.12.3712","article-title":"Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients","volume":"96","author":"Salven","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2011.03.002_bib203","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.2353\/ajpath.2007.060901","article-title":"Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes","volume":"170","author":"Gratzinger","year":"2007","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.beha.2011.03.002_bib204","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/08977199209023937","article-title":"The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies","volume":"7","author":"Kim","year":"1992","journal-title":"Growth Factors"},{"issue":"6423","key":"10.1016\/j.beha.2011.03.002_bib205","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/362841a0","article-title":"Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo","volume":"362","author":"Kim","year":"1993","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.beha.2011.03.002_bib206","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1080\/10428190902856808","article-title":"A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108","volume":"50","author":"Stopeck","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"10.1016\/j.beha.2011.03.002_bib207","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2011.03.002_bib208","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/0008-5472.671.65.3","article-title":"Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies","volume":"65","author":"Gerber","year":"2005","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.beha.2011.03.002_bib209","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1080\/10428190600563821","article-title":"Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis","volume":"47","author":"Ganjoo","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"10.1016\/j.beha.2011.03.002_bib210","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2011.03.002_bib211","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.2967\/jnumed.109.067587","article-title":"Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial","volume":"50","author":"Delaloye","year":"2009","journal-title":"J Nucl Med"},{"issue":"32","key":"10.1016\/j.beha.2011.03.002_bib212","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T17:42:57Z","timestamp":1686073377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692611000296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":212,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S1521692611000296"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2011.03.002","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}